Prophase Labs (PRPH) Proxy Filing summary

Executive summary

• Special Meeting scheduled for August 29, 2025, to vote on six key proposals impacting equity compensation, capital structure, share repurchase, and governance.

• Board recommends approval of all proposals, including major increases in authorized shares and new equity plans.

• Proposals support a strategic shift toward a crypto treasury strategy and provide flexibility for future growth and capital needs.

Voting matters and shareholder proposals

• Proposal 1: Amend and supersede the 2022 Equity Compensation Plan, increasing shares by 3,000,000 and adopting the 2025 Plan.

• Proposal 2: Amend and supersede the 2022 Directors' Equity Compensation Plan, increasing shares by 500,000 and adopting the 2025 Directors' Plan.

• Proposal 3: Amend Certificate of Incorporation to increase authorized common stock from 50M to 1B shares, enabling a crypto treasury strategy.

• Proposal 4: Advisory approval of a $15M share repurchase program, discretionary and subject to market conditions.

• Proposal 5: Approve issuance of up to 226,310,704 shares in a private placement, potentially exceeding 20% of outstanding shares.

• Proposal 6: Amend Bylaws to designate the principal executive office address.

Board of directors and corporate governance

• Board consists of four directors, including independent members with expertise in finance, medicine, and technology.

• Board committees include Audit, Compensation, and Nominating & Corporate Governance.

• New director appointed in 2025, bringing additional legal and fintech experience.

• Bylaws updated to clarify nomination and business proposal procedures for shareholders.